Propranolol as a treatment for deep infantile hemangioma: case report

Abstract

Background: Infantile hemangiomas (IH) are common neoplasms composed of proliferating endothelial cells. The duration and the growth rate are variable; some grow very slowly, while others grow rapidly and at an unpredictable rate. Despite the relative frequency of IH and the possible severity of complications, there are currently no uniform treatment guidelines. Although most are not worrisome, about 12% of IHs are significantly complex; propranolol has been adopted as a treatment.

Objective: Report a clinical case of lactanate with hemangioma treated with propranolol.

Case report: A healthy newborn is presented, with the presence of small telangiectasias in the right hemicervical region without association with obstetric trauma; of a healthy 31-year-old mother. During its evolution at 3 months of age, the area covered with telangiectasias turned deep blue and the growth of a protrusion began, ultrasound and angiography, showed soft tissues of the posterior cervical space a lobulated mass of 9.1x4.1x4.9cm in its longitudinal and transverse diameter respectively, diagnosing it as a deep hemangioma; which was treated with propranolol.

Discussion: Asymptomatic newborns with infantile neck hemangiomas are clinically controlled for the first six months of life, 60% of them develop life-threatening airway symptoms; the identification of the hemangioma was due to its rapid growth and not due to the alteration of surrounding structures that put the well-being of the infant at risk. Regarding the application of Propranolol, its administration was immediately after its identification, to avoid future complications.

Conclusion: Administration of propranolol systemically eliminates the characteristic color and reduces the size of the hemangioma.

Keywords: hemangioma, propranolol, imaging, management

Background

Infantile hemangiomas (IH) are common benign tumors composed of proliferating endothelial cells, their duration and growth rate are variable; some infants will have poorly growing hemangiomas, others grow rapidly and at an unpredictable rate, most are risk-free, 12% are complex.

Vascular alterations of blood and lymphatic vessels are heterogeneous and the International Society for the Study of Vascular Anomalies (ISSVA) has classified them as tumors and vascular alterations. Among the vascular tumors are IH, the prevalence in the general Caucasian population of 4.5% being more common in women, associated with a possible synergy between the vascular endothelial growth factor and estradiol. They generally manifest in a single form of erythematous or erythematous-violaceous coloration, arising from childbirth, Figure 1.

The diagnosis is basically clinical; Contrast MRI imaging evaluation is used to define the type, size, and extent of the lesion. The treatment of a patient with IH is individualized, depending on factors such as size of lesion, location, presence of complications such as ulceration, risk of scarring or disfigurement, age of the patient, rate of growth or involution at the time of diagnosis, risks and benefits of administering the treatment. We present the case of an infant with a diagnosis of deep IH in connection, treated with propranolol.

Case report

A healthy 31-year-old mother, pregnancy 1, delivery 1, normal pregnancy course, obtaining by eutocic delivery at 40.4 weeks of gestation with APGAR 9 and 10 in minutes 1 and 5, weight of 3005g and height of 48cm.

The healthy newborn which apparently does not present any alteration, only small telangiectasias were observed in the right hemicervical region, which was initially associated with possible trauma resulting from childbirth, Figure 1.

At three months of age, the area covered with telangiectasias turned deep blue and the growth of a lump began, Figure 2; At 4 months to 3 weeks of age, an increase in the volume of the right hemicervical region was observed, performed using abdominal ultrasound with Doppler to rule out alterations, observing liver with well-defined borders, bile ducts (intra and extrahepatic), vascular pattern, pancreas, kidneys, cortex of the medulla, bladder and intestinal loops with normal parameters. In addition, the electrocardiogram did not find any alteration (PSVD 15mmHg and LVEF 6% AF32%) and the hemostasis profile showed normal values except for a decrease in activated partial thromboplastin time.
Propranolol as a treatment for deep infantile hemangioma: case report

A, B) show infantile hemangioma at 4 months of age. C) Image of the 4-day-old newborn, in which no protrusions are observed. D) and E) three-dimensional reconstruction of the magnetic resonance image, the structure shows the origin of branching of the subclavian artery. (Image 2A, 2B, 2C, 2D and 2E).

Figure 1 Image of the 4-day-old newborn, in which no protrusions are observed on the right hemicervical, indicating the development of a hemangioma.

Figure 2 A, B) show infantile hemangioma at 4 months of age. C) Angioresonance, where it can be seen how the hemangioma is inserted below the hemicervical neck and D, E) three-dimensional reconstruction of the magnetic resonance image, the structure shows the origin of branching of the hemangioma.

With the results of the angio-resonance study, it was observed that the patient had a deep alteration in the vascular system of the upper part of the trunk, diagnosing it as deep IH.

Hemangioma management

The treatment can be topical and systemic, within the topical treatment are timolol, propranolol, imiquimod, topical corticosteroids, brimonidine and lasers, finally, in the systemic treatment beta-adrenergic blockers, propranolol, atenolol, systemic corticosteroids can be used, vincristine and IFN-α 2a or 2b. Propranolol is a synthetic β-adrenergic receptor blocking agent that is classified as non-selective because it blocks β-1 and β-2 adrenergic receptors. Chronotropic, inotropic, and vasodilatory responses decrease proportionally when propranolol blocks the β receptor site, resulting in a decrease in heart rate and blood pressure, and the mechanism of action of propranolol on HI has not yet been clearly defined. Some of the proposed hypotheses include vasoconstriction, decreased renin production, inhibition of angiogenesis, and stimulation of apoptosis. Medical management is highly individualized, and oral propranolol treatment is considered in the presence of ulceration, impairment of vital function (ocular involvement or airway obstruction), or risk of permanent disfigurement. The patient started with 10mg tablets of propranolol, taking: first week: ½ tablet in the morning, second week: 1 tablet in the morning and ½ at night, and third week: 1 tablet in the morning and 1 at night, continuing in this way until the doctor indicated the suspension of the medication. A week after the start of treatment, the diagnosis of deep IH was confirmed, because the medication with propranolol allowed the reduction of the hemangioma by up to 50%.

After 1.4 years of treatment, treatment reduction began, because the IH reduced its size until it was completely flat, with only a small amount of telangiectasia being observed, Figure 3.

Finally, 4 months after suspension of treatment (1.8 years of age), it was possible to observe recurrence with small growth of HI, making the decision to resume treatment with Propranolol. Currently, at 2 years of age, the patient continues with propranolol 20mg/day with a totally flat hemangioma and a small amount of telangiectasia.

Discussion

HI is the most common vascular tumor affecting children that appears in the first 2 weeks of life; as was our case and a proliferative phase continues that continues during the first year of life. The characteristic proliferative phase of HI occurs in the first year of life, with maximum growth during the first 6 months after birth, during which it increases in size, depth, and color, with an increasing possibility of bleeding and ulceration. The involution phase begins thereafter and can continue for up to 5 or even 10 years.

IHs are frequently located on the head and neck (80%), followed by the trunk and extremities. Most are small and do not require treatment, their location, size and distribution can affect neighboring structures, which can be associated with abnormalities that affect the integrity of the baby. It is estimated that 1–10% of IHs are associated with significant morbidity, mainly in the form of concomitant malformations.

Conclusion

In IH that do not affect adjacent organs, the application of propranolol improves the aesthetics of the patient and reduces the risk of possible complications in the future. The application of 2mg/kg/day of Propranolol systemically, eliminates the characteristic color and reduces the size of the HI, is a safe treatment and has no adverse effects, for which observational studies agree on its use as first-line treatment.

Acknowledgments

None.

Citation: Estuardo LJ, Carlos DM, Daniela AR, et al. Propranolol as a treatment for deep infantile hemangioma: case report. Obstet Gynecol Int J. 2021;12(5):302-304. DOI: 10.15406/ogij.2021.12.00596
Funding
None.

Conflicts of interest
The authors declare that there is no conflict of interest.

References
1. Beth A Drolet, Peter C Frommelt, Sarah L Chamlin, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128–140.
2. Morán E, Campos B, García M, et al. Most frequent vascular anomalies in pediatric patients. Part 1: Vascular tumors. Acta Pediátrica de México. 2020;41(1):26–39.
3. G Lizardo, D Velásquez, B Cruz. Rapidly involutional congenital hemangioma. Revista Médica Honduras. 2015;83(3):130–133.
4. M Larralde, J Sóle, P Luna, et al. Rapidly involutional congenital hemangiomas. Series of 25 cases. Archivos argentinos de pediatria. 2014;112(2):e61–e65.
5. Brahmbhatt A, Skalski K, Bhatt A. Vascular lesions of the head and neck: an update on classification and imaging review. Insights into Imaging. 2020;11(19):1–18.
6. María del Pilar González-Díaz, Laura Isabel Ramos-Gómez, Jesús Manuel Yañez-Sánchez, et al. Systemic use of propranolol in the treatment of infantile hemangiomas. Revista Mexicana de Oftalmología. 2011;83(4):205–214.
7. Al-Mayoof AF, Joda AE, Alnushhadany OE. Propranolol therapy in infantile hemangioma: correlation of age and duration of treatment to the outcomes. Ann Pediatr Surg. 2019;15(8).
8. Cherif O, Novelo A, Orozco L, et al. Infantile hemangioma: update of topical and systemic treatment. Boletín Médico del Hospital Infantil de México. 2019;76:167–175.
9. Lobos C. Childhood hemangiomas, current management. Revista Médica Clínica Las Condes. 2011;22(6):825–833.
10. Schwartz R, Sidor M, Musumeci M, et al. Infantile haemangiomas: a challenge in paediatric dermatology. Journal of the European Academy of Dermatology and Venereology. 2010;24:631–638.
11. Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. Pediatric Dermatology. 1997;14:173–179.
12. Torres B. Diagnostic action protocol for angiomas in childhood skin. Piel. 2008;23(5):249–257.
13. Orlow S, Isakoff M, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a “beard” distribution. The Journal of Pediatrics. 1997;131:643–646.
14. Hervella M Iglesias. Vascular tumors as syndromic markers. Anales del sistema sanitario de Navarra. 2004;27(1):33–44.
15. Léauté C, Hubiche T, Boralevi F, et al. Beta-blockates: an alternative to general corticotherapy in the treatment of infantile hemangiomas. Comunicación oral. Journées Dermatologique de Paris, Société Française de Dermatologie. Paris, Francia; 2007:4–8.
16. Moredo D, De la Peña T, Matos V, et al. Presentation of 3 cases of infantile hemangiomas treated with propranolol. Revista Cubana de Pediatría. 2011;83(3):316–322.
17. Léauté C, Hubiche T, Boralevi F, et al. Propranolol for severe hemangiomas of infancy. The New England Journal of Medicine. 2008;358(2):249–251.
18. Deza P, Araujo M, Rojas P. Propranolol in the treatment of infantile hemangiomas: a case report. Dermatología Peruana. 2014;24(4):246–249.
19. Bras S, Amaro C, Mendes P. Rapidly involuting congenital hemangioma. Anais Brasileiros de Dermatologia. 2017;92(6):861–863.